TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

UnitedHealth Group Incorporated (UNH)

Healthcare Healthcare Plans
414.40 $
-1.7% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at UnitedHealth Group Incorporated.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 2 of our scanner strategies — each hit links to the scanner.

Aktien.Guide
Dividends

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
421.50$
Open
422.00$
Day High
422.80$
Day Low
414.10$
Volume
3,899,689shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
237.80 $ 436.40 $
08/01/2025 07/21/2026

Current price 414.40 $ — 89% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
374.0$B
Shares Outstanding
908Mio.
Float
99.5%
Beta
0.6

Performance

Perf. 1M
10.40%
Perf. 3M
63.00%
Perf. 6M
29.90%
YTD Performance (%)
25.70%
52-Week-High Distance
-0.5%
Perf. 1Y
70.50%
Perf. 3Y
-13.05%
Perf. 5Y
9.74%
Perf. 10Y
241.28%
Perf. Since Inception
377,313.48%

Technical Indicators

MA 38 Days
418.40$
MA 50 Days
410.20$
MA 200 Days
344.70$
RSI (14)
47.0
Volatility 30 Days
26.5%
Volatility 250 Days
38.7%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
32.2
Forward P/E
20.9
PEG
1.3
P/B
4.0
P/S
0.8
EV/EBITDA
18.5
Price/FCF
19.0

Profitability

Gross Margin
19.5%
EBIT Margin
8.1%
Net Margin
3.1%
Return on Equity
12.2%
Return on Assets
4.4%

Balance Sheet & Safety

Equity Ratio
33.2%
negative equity
Debt/Equity
-11.8
Altman Z″
4.74
Piotroski
5 out of 9

Growth

Sales Growth Last Quarter
2.00%
EPS Growth Last Quarter
0.70%
Sales Growth (Year)
11.81%
Forward Sales Growth
2.72%
Forward EPS Growth
13.80%

Dividend

Dividend Yield
2.24%
Dividend Per Share (TTM)
8.95$
Payout Ratio
48.0%
Years Without a Cut
35Years
Increase Streak
16Years

Quality & Screener

Stage
2
RS Rating
80
EPS Rating
52
Piotroski
5 out of 9
Fundamental Rating
C (52 out of 100)
Altman Z″
4.74

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 414.40 $
Price Target (average) 475.23 $

The price target sits 14.7% above the current price.

Consensus
Sell
Analyst Ratings
27
Distribution of Recommendations
Strong Buy 14
Buy 6
Hold 5
Sell 1
Strong Sell 1

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 19.81 18.40 – 20.11 446,534 21.2% 25
12/31/2027 22.44 19.92 – 24.50 459,373 13.2% 27

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

27. Oct 2026 · before the open · Q3 2026
Expected Earnings per Share
4.08 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 100,807.0 $M Q4 2025: Q1 · 109,575.0 $M Q1 2025: Q2 · 111,616.0 $M Q2 2025: Q3 · 113,161.0 $M Q3 2025: Q4 · 113,215.0 $M Q4 2026: Q1 · 111,721.0 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 5.98 2.50 100,807 6.80 5.50 2,369 1,457
2025: Q1 6.85 109,575 9.80 5.70 5,456 4,558
2025: Q2 3.74 -17.60 111,616 12.90 3.10 7,188 6,302
2025: Q3 2.57 -60.50 113,161 12.20 2.10 5,945 5,055
2025: Q4 0.01 -99.80 113,215 12.30 0.00 1,108 160
2026: Q1 6.90 0.70 111,721 2.00 5.60 8,912 8,149
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 184,840 12,930 7,017 7.25 9,795 38,397 122,679
2017 201,159 15,209 10,558 10.72 13,596 49,833 139,057
2018 226,247 17,344 11,986 12.19 15,713 51,696 152,221
2019 242,155 19,685 13,839 14.33 18,463 57,616 173,889
2020 257,141 22,405 15,403 16.03 22,174 65,491 197,289
2021 287,597 23,970 17,285 18.08 22,343 71,760 212,206
2022 324,162 28,435 20,120 21.18 26,206 77,772 245,705
2023 371,622 32,358 22,381 23.86 29,068 88,756 273,720
2024 400,278 32,287 14,405 15.51 24,204 92,658 298,278
2025 447,567 18,964 12,056 13.25 19,697 94,110 309,581

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

UnitedHealth Group Incorporated ist ein Gesundheitsunternehmen mit Geschäft in den USA und international. Es ist in vier Segmenten tätig: Optum Health, Optum Insight, Optum Rx und UnitedHealthcare.

Employees390,000
HeadquartersEden Prairie, MN
Address1 Health Drive, 55344 Eden Prairie, United States
Phone(800)-328-5979
Websiteunitedhealthgroup.com
IPO Date26. Oct 1984
ISINUS91324P1021
Stock Split2:1 on 05/31/2005

Management

Management
Name Title Birth Year
Stephen J. Hemsley CEO & Non-Independent Non-Executive Chairman 1953
Wayne Scott DeVeydt Chief Financial Officer 1970
Christopher R. Zaetta Executive VP, Chief Legal Officer & Corporate Secretary 1972
Timothy John Noel Chief Executive Officer of UnitedHealthcare Business 1972
Patrick Hugh Conway M.D., M.Sc. Chief Executive Officer of Optum 1975
Dennis Stankiewicz Chief Accounting Officer & Corporate Controller 1978
Sandeep Dadlani Executive VP and Chief Digital & Technology Officer 1975
Zachary William Sopcak Senior Vice President of Capital Markets Communications & Investor Relations
Erin L. McSweeney J.D. Executive VP & Chief People Officer 1965
Richard J. Migliori M.D. Executive Vice President & Senior Advisor 1957

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?